Short-term glucose metabolism and gut hormone modulations after billroth ii gastrojejunostomy in nonobese gastric cancer patients with type 2 diabetes mellitus, impaired glucose tolerance and normal glucose tolerance

Archives of Medical Research

Volumn 44, Issue 6, 2013, Pages 437-443

  Zhang, Xiao juan ^a   Xiao, Zhu ^b   Yu, Hong ling ^a   Zhang, Xiang xun ^a   Cheng, Zhong ^a   Tian, Hao ming ^a  

^a SICHUAN UNIVERSITY   (China)

^b The First People's Hospital of Chengdu   (China)

Author keywords

Billroth II gastrojejunostomy; Glucose metabolism; Gut hormones; Roux en Y gastric bypass; Type 2 diabetes mellitus

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; PEPTIDE YY;

ADULT; AGED; ARTICLE; BODY WEIGHT; CANCER PATIENT; CLINICAL ARTICLE; FEMALE; GASTRECTOMY BILLROTH II; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; STOMACH CANCER; VOMITING; WEIGHT REDUCTION;

BILLROTH II GASTROJEJUNOSTOMY; GLUCOSE METABOLISM; GUT HORMONES; ROUX-EN-Y GASTRIC BYPASS; TYPE 2 DIABETES MELLITUS;

ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC BYPASS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED; OBESITY; PEPTIDE YY; POSTOPERATIVE PERIOD; STOMACH NEOPLASMS; WEIGHT LOSS;

EID: 84885106243     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.07.004     Document Type: Article

References (28)

1. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
2. Standards of medical care in diabetes-2010. Diabetes Care 2010, 33(suppl):S11-S61. American Diabetes Association.
3. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292:1724-1737.
4. Mingrone G., Panunzi S., De Gaetano A., et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012, 366:1577-1585.
5. Schauer P.R., Kashyap S.R., Wolski K., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012, 366:1567-1576.
6. Lee W.J., Chen C.Y., Chong K., et al. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis 2011, 7:683-690.
7. Caiazzo R., Zerrweck C., Verhaeghe R., et al. Gastric bypass and glucose metabolism. Diabetes Metab 2009, 35:528-531.
8. Bose M., Oliván B., Teixeira J., et al. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidences?. Obes Surg 2009, 19:217-229.
9. Le Roux C.W., Aylwin S.J., Batterham R.L., et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006, 243:108-114.
10. Korner J., Bessler M., Inabnet W., et al. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 2007, 3:597-601.
11. Lee W., Ahn S.H., Lee J.H., et al. Comparative study of diabetes mellitus resolution according to reconstruction type after gastrectomy in gastric cancer patients with diabetes mellitus. Obes Surg 2012, 22:1238-1243.
12. 2. J Korean Surg Soc 2012, 82:347-355.
13. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
14. Phillips D.I., Clark P.M., Hales C.N., et al. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994, 11:286-292.
15. Allison D.B., Paultre F., Maggio C., et al. The use of areas under curves in diabetes research. Diabetes Care 1995, 18:245-250.
16. Drucker D.J. Glucagon-like peptides. Diabetes 1998, 47:159-169.
17. Perfetti R., Zhou J., Doyle M.E., et al. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000, 141:4600-4605.
18. Vilsboll T., Holst J.J. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004, 47:357-366.
19. Asmar M. New physiological effects of the incretin hormones GLP-1 and GIP. Dan Med Bull 2011, 58:B4248.
20. Le Roux C.W., Batterham R.L., Aylwin S.J., et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 2006, 147:3-8.
21. Hage M.P., Safadi B., Salti I., et al. Role of gut-related peptides and other hormones in the amelioration of type 2 diabetes after Roux-en-Y gastric bypass surgery. ISRN Endocrinol 2012, 2012:504756.
22. Pöykkö S.M., Kellokoski E., Hörkkö S., et al. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003, 52:2546-2553.
23. Chen C.Y., Fujimiya M., Laviano A., et al. Modulation of ingestive behavior and gastrointestinal motility by ghrelin in diabetic animals and humans. J Chin Med Assoc 2010, 73:225-229.
24. Bittner R., Bittner B., Beger H.G. (Homeostasis of glucose and gastric resection. The influence of the food passage through the duodenum [author's transl]). Z Gastroenterol 1981, 19:698-707.
25. Schwarz A., Büchler M., Usinger K., et al. Importance of the duodenal passage and pouch volume after total gastrectomy and reconstruction with the Ulm pouch: prospective randomized clinical study. World J Surg 1996, 20:60-67.
26. Kalmár K., Németh J., Kelemen D., et al. Postprandial gastrointestinal hormone production is different, depending on the type of reconstruction following total gastrectomy. Ann Surg 2006, 243:465-471.
27. Cohen R.V., Rubino F., Schiavon C., et al. Diabetes remission without weight loss after duodenal bypass surgery. Surg Obes Relat Dis 2012, 8:e66-e68.
28. Rubino F., Forgione A., Cummings D.E., et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006, 244:741-749.